Targeting the IDO1 pathway in cancer: from bench to bedside

[1]  A. Chiarugi,et al.  Expression of Indoleamine 2,3-Dioxygenase Induced by IFN-γ and TNF-α as Potential Biomarker of Prostate Cancer Progression , 2018, Front. Immunol..

[2]  Asher Mullard.  IDO takes a blow , 2018, Nature Reviews Drug Discovery.

[3]  Xu Wang,et al.  miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy , 2018, Journal of Hematology & Oncology.

[4]  Shanshan Zhu,et al.  High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer , 2018, Front. Immunol..

[5]  W. Horninger,et al.  High IDO‐1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma , 2018, Cancer science.

[6]  S. Pushalkar,et al.  The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. , 2018, Cancer discovery.

[7]  Kongming Wu,et al.  Gut microbiome modulates efficacy of immune checkpoint inhibitors , 2018, Journal of Hematology & Oncology.

[8]  A. Minn,et al.  Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. , 2018, Immunity.

[9]  Y. Lou,et al.  Next generation of immune checkpoint therapy in cancer: new developments and challenges , 2018, Journal of Hematology & Oncology.

[10]  C. James,et al.  IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma , 2018, Clinical Cancer Research.

[11]  Yulong Yin,et al.  Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism , 2018, Front. Cell. Infect. Microbiol..

[12]  Z. Karányi,et al.  The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy , 2018, Front. Immunol..

[13]  A. York.  Microbiome: Gut microbiota sways response to cancer immunotherapy , 2018, Nature Reviews Microbiology.

[14]  Y. Lou,et al.  Cancer immunotherapy beyond immune checkpoint inhibitors , 2018, Journal of Hematology & Oncology.

[15]  Li Zhang,et al.  Hypoxia enhances indoleamine 2,3-dioxygenase production in dendritic cells , 2018, Oncotarget.

[16]  J. Janik,et al.  Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod , 2018, Cancer Immunology Research.

[17]  Laurence Zitvogel,et al.  Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.

[18]  E. Le Chatelier,et al.  Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.

[19]  Lijun Sun,et al.  Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities. , 2017, Trends in pharmacological sciences.

[20]  G. Prendergast,et al.  Discovery of IDO1 Inhibitors: From Bench to Bedside. , 2017, Cancer research.

[21]  A. Mondal,et al.  Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'. , 2017, Trends in cancer.

[22]  Yongping Song,et al.  Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy , 2017, Journal of Hematology & Oncology.

[23]  Yongping Song,et al.  Clinical trials of CAR-T cells in China , 2017, Journal of Hematology & Oncology.

[24]  P. Li,et al.  Incorporation of functional elements enhances the antitumor capacity of CAR T cells , 2017, Experimental Hematology & Oncology.

[25]  J. Klánová,et al.  Urinary intermediates of tryptophan as indicators of the gut microbial metabolism. , 2017, Analytica chimica acta.

[26]  Xiangshi Tan,et al.  Heme-containing enzymes and inhibitors for tryptophan metabolism. , 2017, Metallomics : integrated biometal science.

[27]  C. Penning,et al.  A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. , 2017, Gynecologic oncology.

[28]  Zhiqiang Yan,et al.  Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia , 2017, Journal of Hematology & Oncology.

[29]  C. Chai,et al.  Intestine-Specific Homeobox Gene ISX Integrates IL6 Signaling, Tryptophan Catabolism, and Immune Suppression. , 2017, Cancer research.

[30]  Marc Hennequart,et al.  Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance , 2017, Cancer Immunology Research.

[31]  J. Desai,et al.  Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial , 2017 .

[32]  Xi Zhang,et al.  Engineering CAR-T cells , 2017, Biomarker Research.

[33]  G. Du,et al.  Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model , 2017, International journal of immunopathology and pharmacology.

[34]  K. Morrissey,et al.  A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors. , 2017 .

[35]  D. Munn,et al.  IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment , 2017, Cancer Immunology, Immunotherapy.

[36]  Xiaolong Zhang,et al.  The development of bispecific antibodies and their applications in tumor immune escape , 2017, Experimental Hematology & Oncology.

[37]  He Huang,et al.  Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia , 2017, Experimental Hematology & Oncology.

[38]  E. Hsueh,et al.  Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response , 2017, Biomarker Research.

[39]  David M. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[40]  M. Bower,et al.  INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology , 2017, ACS medicinal chemistry letters.

[41]  D. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[42]  P. O'dwyer,et al.  First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies , 2017, Clinical Cancer Research.

[43]  A. Mondal,et al.  IDO1 is an Integral Mediator of Inflammatory Neovascularization , 2016, EBioMedicine.

[44]  S. Rajagopal,et al.  Determination of epacadostat, a novel IDO1 inhibitor in mouse plasma by LC-MS/MS and its application to a pharmacokinetic study in mice. , 2016, Biomedical chromatography : BMC.

[45]  Douglas B. Johnson,et al.  Combinatorial approach to cancer immunotherapy: strength in numbers , 2016, Journal of leukocyte biology.

[46]  Paolo Vicini,et al.  Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors , 2016 .

[47]  Qingsheng Li,et al.  Tolerogenic Phenotype of IFN-γ–Induced IDO+ Dendritic Cells Is Maintained via an Autocrine IDO–Kynurenine/AhR–IDO Loop , 2016, The Journal of Immunology.

[48]  M. Brechbiel,et al.  The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells , 2016, Oncotarget.

[49]  T. Eleftheriadis,et al.  Differential effects of the two amino acid sensing systems, the GCN2 kinase and the mTOR complex 1, on primary human alloreactive CD4⁺ T-cells. , 2016, International journal of molecular medicine.

[50]  John D. Roberts,et al.  A phase I study of indoximod in patients with advanced malignancies , 2016, Oncotarget.

[51]  D. Munn,et al.  IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. , 2016, Trends in immunology.

[52]  Jia Hua Cheng,et al.  Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation , 2016, Oncogenesis.

[53]  C. Rodrigues,et al.  Tolerogenic IDO+ Dendritic Cells Are Induced by PD-1-Expressing Mast Cells , 2016, Front. Immunol..

[54]  Loise M. Francisco,et al.  The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment , 2015, Science Advances.

[55]  J. Wolchok,et al.  Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. , 2015, Cell reports.

[56]  Andrew C. Terentis,et al.  Role of indoleamine 2,3-dioxygenase in health and disease. , 2015, Clinical science.

[57]  T. McGaha,et al.  The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity , 2015, Proceedings of the National Academy of Sciences.

[58]  P. Verhoest,et al.  Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway. , 2015, Journal of medicinal chemistry.

[59]  H. Heslop,et al.  Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. , 2015, Blood.

[60]  Olivier Michielin,et al.  Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. , 2015, Journal of medicinal chemistry.

[61]  U. Grohmann,et al.  The Coevolution of IDO1 and AhR in the Emergence of Regulatory T-Cells in Mammals , 2015, Front. Immunol..

[62]  B. J. Van den Eynde,et al.  Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance , 2015, Oncoimmunology.

[63]  I. Svane,et al.  Indoleamine 2,3-dioxygenase vaccination , 2015, Oncoimmunology.

[64]  D. Munn,et al.  Abstract 5023: Synergistic antitumor effects of combinatorial immune checkpoint inhibition with anti-PD-1/PD-L antibodies and the IDO pathway inhibitors NLG-919 and indoximod in the context of active immunotherapy , 2014 .

[65]  Hui Li,et al.  Noncanonical NF-κB Activation Mediates STAT3-Stimulated IDO Upregulation in Myeloid-Derived Suppressor Cells in Breast Cancer , 2014, The Journal of Immunology.

[66]  E. Dees,et al.  A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors , 2014, Oncotarget.

[67]  G. Prendergast,et al.  Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer , 2014, Cancer Immunology, Immunotherapy.

[68]  Xiaodong Chen,et al.  Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. , 2014, Cancer research.

[69]  I. Svane,et al.  Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase , 2013, Clinical Cancer Research.

[70]  I. Svane,et al.  Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an HLA-A2-restricted epitope derived from indoleamine 2,3 dioxygenase , 2013, Journal of Immunotherapy for Cancer.

[71]  J. Wolchok,et al.  Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 , 2013, The Journal of experimental medicine.

[72]  Charles J. Link,et al.  Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. , 2013 .

[73]  Juntian Liu,et al.  Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer , 2013, The Journal of Immunology.

[74]  D. Munn,et al.  Indoleamine 2,3 dioxygenase and metabolic control of immune responses. , 2013, Trends in immunology.

[75]  G. Prendergast,et al.  IDO inhibits a tryptophan sufficiency signal that stimulates mTOR , 2012, Oncoimmunology.

[76]  Atique U. Ahmed,et al.  IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival , 2012, Clinical Cancer Research.

[77]  Danli Xie,et al.  Tumor suppressor TSC1 is critical for T-cell anergy , 2012, Proceedings of the National Academy of Sciences.

[78]  G. Prendergast,et al.  IDO is a nodal pathogenic driver of lung cancer and metastasis development. , 2012, Cancer discovery.

[79]  C. Decaestecker,et al.  Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer , 2011, British Journal of Cancer.

[80]  C. Piccirillo,et al.  Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives , 2011, Clinical Cancer Research.

[81]  M. Weller,et al.  An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor , 2011, Nature.

[82]  S. Bicciato,et al.  Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells , 2011, Nature Immunology.

[83]  D. Munn,et al.  Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. , 2009, Blood.

[84]  G. Prendergast,et al.  Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase , 2008, Proceedings of the National Academy of Sciences.

[85]  F. Matsumura,et al.  Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. , 2008, Biochemical and biophysical research communications.

[86]  W. Zimmermann,et al.  Expression of Indoleamine 2,3-Dioxygenase in Tumor Endothelial Cells Correlates with Long-term Survival of Patients with Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[87]  D. Munn,et al.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.

[88]  U. Grohmann,et al.  The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.

[89]  B. Baban,et al.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.

[90]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.

[91]  U. Grohmann,et al.  Modulation of tryptophan catabolism by regulatory T cells , 2003, Nature Immunology.

[92]  G. Damonte,et al.  Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase , 2002, The Journal of experimental medicine.

[93]  Milton W. Taylor,et al.  Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation , 2000, The Journal of Immunology.

[94]  D. Munn,et al.  Inhibition of  T Cell Proliferation by Macrophage Tryptophan Catabolism , 1999, The Journal of experimental medicine.

[95]  Y. Urade,et al.  Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[96]  J. Blay,et al.  Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial , 2018, JAMA oncology.

[97]  Kristen N. Pollizzi,et al.  Regulation of T cells by mTOR: the known knowns and the known unknowns. , 2015, Trends in immunology.